2023
Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor J, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal M, Marianayagam N, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera S, Omay S, Mishra-Gorur K, McGuone D, Morales-Valero S, Fulbright R, Gunel M, Erson-Omay E, Moliterno J. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. Journal Of Neurosurgery 2023, 139: 1648-1656. PMID: 37243548, DOI: 10.3171/2023.4.jns222929.Peer-Reviewed Original ResearchConceptsSubtotal resectionSupratentorial tumorsElevated Ki-67High-risk featuresProgression-free survivalChromosome 1p deletionInfratentorial counterpartsInfratentorial tumorsPostoperative managementSomatic driver mutationsCerebral convexityGrade IIInfratentorial meningiomasKi-67Posterior fossaLoss of heterozygosityMeningiomasResectionTumorsWhole-exome sequencing dataDriver mutationsHigh gradeSignificant differencesExome sequencing dataSporadic meningiomas
2021
NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS
Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.Peer-Reviewed Original ResearchSphenoid wing meningiomaSpheno-orbital meningiomasBony involvementTRAF7 mutationsTumor invasionGenomic subgroupsPre-operative clinical featuresYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionLogistic regression modelsWhole-exome sequencingClinical featuresClinical variablesGrade IIPredictive logistic regression modelRecurrence patternsMolecular subtypesClinical implicationsExome sequencingHyperostosisMeningiomasTumorsGenomic driversPIK3CA mutation in a case of CTNNB1 mutant sinonasal glomangiopericytoma
Hong C, Khan M, Sukys J, Prasad M, Erson-Omay EZ, Vining E, Omay SB. PIK3CA mutation in a case of CTNNB1 mutant sinonasal glomangiopericytoma. Molecular Case Studies 2021, 8: mcs.a006120. PMID: 34667073, PMCID: PMC8744496, DOI: 10.1101/mcs.a006120.Peer-Reviewed Original ResearchConceptsCase of glomangiopericytomaWhole-exome sequencingInstitutional review board-approved protocolTargeted medical therapyUnderwent surgical resectionPI3K/Akt/mTORWnt/β-cateninAkt/mTORPrimary sinonasal tumorSurgical resectionClinicopathologic characteristicsMedical therapyRare tumorPIK3CA mutationsSinonasal tumorsGlomangiopericytomaTumorsΒ-cateninSomatic mutationsComprehensive genetic characterizationGenomic characterizationMutationsConcurrent dysregulationResectionSinonasalType of bony involvement predicts genomic subgroup in sphenoid wing meningiomas
Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.Peer-Reviewed Original ResearchConceptsSpheno-orbital meningiomasSphenoid wing meningiomaBony involvementTRAF7 mutationsGenomic subgroupsPre-operative clinical featuresTumor invasionYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionWhole-exome sequencingBone involvementBone invasionClinical featuresClinical variablesGrade IIMolecular subtypesRecurrence patternsClinical implicationsHyperostosisExome sequencingMeningiomasTumorsGenomic drivers
2020
Case Report: Suprasellar Pituitary Adenoma Presenting With Temporal Lobe Seizures
Hong CS, Gorrepati R, Kundishora AJ, Elsamadicy AA, Peter PR, Damisah EC, Manes RP, Omay SB. Case Report: Suprasellar Pituitary Adenoma Presenting With Temporal Lobe Seizures. Frontiers In Surgery 2020, 7: 598138. PMID: 33335912, PMCID: PMC7736041, DOI: 10.3389/fsurg.2020.598138.Peer-Reviewed Case Reports and Technical NotesPituitary macroadenomaTemporal lobeFurther seizure activityTemporal lobe seizuresYear old maleMass effectLeft temporal lobeSuprasellar pituitary adenomasEndocrine dysfunctionGeneralized seizuresSeizure activityPituitary pathologyPituitary adenomasMedical treatmentSeizuresEndoscopic endonasalMacroadenomasLobePatientsDysfunctionAdenomasSymptomsTumorsEndonasalPathology
2017
Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB, Chen YN, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, Greenfield JP, Souweidane MM, Kacker A, Pisapia DJ, Anand VK, Schwartz TH. Do craniopharyngioma molecular signatures correlate with clinical characteristics? Journal Of Neurosurgery 2017, 128: 1473-1478. PMID: 28707994, DOI: 10.3171/2017.1.jns162232.Peer-Reviewed Original ResearchConceptsPapillary craniopharyngiomasAdamantinomatous craniopharyngiomaMutation groupPostoperative clinical symptomsSubgroup of tumorsMolecular signaturesWeill Cornell Medical CollegeND tumorsClinical characteristicsCornell Medical CollegeClinical symptomsClinical variablesGroup tumorsRadiographic featuresResults HistologyBRAF mutationsCraniopharyngiomaAge groupsMedical CollegeTumorsExome sequencing studiesCTNNB1 mutationsOutcome variablesHistologyPatients
2016
Chapter 53 Nonneoplastic Mass Lesions of the Central Nervous System
Omay S, Atsina K, Baehring J. Chapter 53 Nonneoplastic Mass Lesions of the Central Nervous System. 2016, 653-665. DOI: 10.1016/b978-0-12-800945-1.00053-7.Peer-Reviewed Original Research
2012
Low-Grade Gliomas When and How to Treat
Omay SB, Piepmeier JM, Knisely JP. Low-Grade Gliomas When and How to Treat. Hematology/Oncology Clinics Of North America 2012, 26: 797-809. PMID: 22794284, DOI: 10.1016/j.hoc.2012.05.001.Peer-Reviewed Original ResearchConceptsSurgical resectionLow-grade gliomasPatient-specific variablesSame imaging techniqueRadiotherapeutic managementUncommon tumorClinical trialsOperative techniqueHistopathologic characterizationGrade gliomasOptimal managementAdditional studiesGliomasResectionAdequate samplesImaging techniquesPatientsPrognosisManagementTumorsTrials
2009
Current concepts and newer developments in the treatment of malignant gliomas
Omay S, Vogelbaum M. Current concepts and newer developments in the treatment of malignant gliomas. Indian Journal Of Cancer 2009, 46: 88-95. PMID: 19346642, DOI: 10.4103/0019-509x.49146.Peer-Reviewed Original ResearchConceptsMalignant gliomasPrimary malignant brain tumorCancer-related disabilityMalignant glioma patientsStandard treatment modalityGlioma cell biologyMalignant brain tumorsNew treatment strategiesTreatment modalitiesChallenging tumorsSystemic administrationNovel therapiesTreatment strategiesAdult cancersGlioma patientsRadiation therapyBrain tumorsTherapyTumorsGliomasCurrent conceptsChemotherapyPatientsSurgeryGreater understanding